Diseases Market Research Reports

Medical Diseases Market Research Reports, Analysis & Trends

 
Publication Single User License (PDF) Price
Hematological Malignancies: Multiple Myeloma (MM) – Early and Robust Diagnosis along with New Treatment Options can have Considerable Impact on Management of the Disease

Hematological Malignancies: Multiple Myeloma (MM) – Early and Robust Diagnosis along with New Treatment Options can have Considerable Impact on Management of the Disease

Date Published: Jan 22 2015
While targeting unmet needs in the treatment of hematological malignancies/ cancer through innovative drug development strategies have witnessed favorable outcomes, the specific choice of the therapies is dependent on the identification of important genomic alterations in cancerous cells that allow for the tumor’s sub classification.  Over the past decade, Proteasome inhibitor and the immunomodulatory drugs have become the cornerstone of treatment for pts with Multiple Myeloma (MM) resulting in improved survival.
$3,000.00
Pneumocystis Infection - Pipeline Review, H2 2014

Pneumocystis Infection - Pipeline Review, H2 2014

Date Published: Dec 31 2014
Pneumocystis Infection Pipeline Review, H2 2014 report provides comprehensive information on the therapeutic development for Pneumocystis Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pneumocystis Infection and special features on late-stage and discontinued projects.
$2,000.00
Corneal Ulcers - Pipeline Review, H2 2014

Corneal Ulcers - Pipeline Review, H2 2014

Date Published: Dec 31 2014
Corneal Ulcers Pipeline Review, H2 2014 report provides comprehensive information on the therapeutic development for Corneal Ulcers, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Corneal Ulcers and special features on late-stage and discontinued projects.
$2,000.00
Phenylketonuria (PKU) - Pipeline Review, H2 2014

Phenylketonuria (PKU) - Pipeline Review, H2 2014

Date Published: Dec 31 2014
Phenylketonuria (PKU) Pipeline Review, H2 2014 report provides comprehensive information on the therapeutic development for Phenylketonuria (PKU), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Phenylketonuria (PKU) and special features on late-stage and discontinued projects.
$2,000.00
Fibrosarcoma - Pipeline Review, H2 2014

Fibrosarcoma - Pipeline Review, H2 2014

Date Published: Dec 31 2014
Fibrosarcoma Pipeline Review, H2 2014 report provides comprehensive information on the therapeutic development for Fibrosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrosarcoma and special features on late-stage and discontinued projects.
 
$2,000.00
Lennox-Gastaut Syndrome - Pipeline Review, H2 2014

Lennox-Gastaut Syndrome - Pipeline Review, H2 2014

Date Published: Dec 31 2014
Lennox-Gastaut Syndrome Pipeline Review, H2 2014 report provides comprehensive information on the therapeutic development for Lennox-Gastaut Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lennox-Gastaut Syndrome and special features on late-stage and discontinued projects.
$2,000.00
Bronchitis - Pipeline Review, H2 2014

Bronchitis - Pipeline Review, H2 2014

Date Published: Dec 31 2014
Bronchitis Pipeline Review, H2 2014 report provides comprehensive information on the therapeutic development for Bronchitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bronchitis and special features on late-stage and discontinued projects.
 
$2,000.00
Articular Cartilage Defect - Pipeline Review, H2 2014

Articular Cartilage Defect - Pipeline Review, H2 2014

Date Published: Dec 31 2014
$2,000.00
Posterior Uveitis - Pipeline Review, H2 2014

Posterior Uveitis - Pipeline Review, H2 2014

Date Published: Dec 31 2014
Posterior Uveitis Pipeline Review, H2 2014 report provides comprehensive information on the therapeutic development for Posterior Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Posterior Uveitis and special features on late-stage and discontinued projects.
$2,000.00
Cervical Dysplasia - Pipeline Review, H2 2014

Cervical Dysplasia - Pipeline Review, H2 2014

Date Published: Dec 31 2014
Cervical Dysplasia Pipeline Review, H2 2014 report provides comprehensive information on the therapeutic development for Cervical Dysplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Dysplasia and special features on late-stage and discontinued projects.
$2,000.00
Thromboembolism - Pipeline Review, H2 2014

Thromboembolism - Pipeline Review, H2 2014

Date Published: Dec 31 2014
Thromboembolism Pipeline Review, H2 2014 report provides comprehensive information on the therapeutic development for Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thromboembolism and special features on late-stage and discontinued projects.
$2,000.00
Oligodendroglioma - Pipeline Review, H2 2014

Oligodendroglioma - Pipeline Review, H2 2014

Date Published: Dec 31 2014
Oligodendroglioma Pipeline Review, H2 2014 report provides comprehensive information on the therapeutic development for Oligodendroglioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Oligodendroglioma and special features on late-stage and discontinued projects.
$2,000.00
Charcot-Marie-Tooth Disease - Pipeline Review, H2 2014

Charcot-Marie-Tooth Disease - Pipeline Review, H2 2014

Date Published: Dec 31 2014
$2,000.00
Follicular Thyroid Cancer - Pipeline Review, H2 2014

Follicular Thyroid Cancer - Pipeline Review, H2 2014

Date Published: Dec 31 2014
$2,000.00
Anterior Uveitis - Pipeline Review, H2 2014

Anterior Uveitis - Pipeline Review, H2 2014

Date Published: Dec 31 2014
Anterior Uveitis Pipeline Review, H2 2014 report provides comprehensive information on the therapeutic development for Anterior Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anterior Uveitis and special features on late-stage and discontinued projects.
$2,000.00
Cholestasis - Pipeline Review, H2 2014

Cholestasis - Pipeline Review, H2 2014

Date Published: Dec 31 2014
Cholestasis Pipeline Review, H2 2014 report provides comprehensive information on the therapeutic development for Cholestasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cholestasis and special features on late-stage and discontinued projects.
 
$2,000.00
Dysmenorrhea - Pipeline Review, H2 2014

Dysmenorrhea - Pipeline Review, H2 2014

Date Published: Dec 31 2014
Dysmenorrhea Pipeline Review, H2 2014 report provides comprehensive information on the therapeutic development for Dysmenorrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dysmenorrhea and special features on late-stage and discontinued projects.
 
$2,000.00
Acute Lymphoblastic Lymphoma - Pipeline Review, H2 2014

Acute Lymphoblastic Lymphoma - Pipeline Review, H2 2014

Date Published: Dec 31 2014
$2,000.00
Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Pipeline Review, H2 2014

Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) - Pipeline Review, H2 2014

Date Published: Dec 31 2014
$2,000.00
Pre-Eclampsia - Pipeline Review, H2 2014

Pre-Eclampsia - Pipeline Review, H2 2014

Date Published: Dec 31 2014
Pre-Eclampsia Pipeline Review, H2 2014 report provides comprehensive information on the therapeutic development for Pre-Eclampsia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pre-Eclampsia and special features on late-stage and discontinued projects.
 
$2,000.00

Pages

Shopping cart

0 Items $0.00
Not able to find what you are looking for?
Call Us
WHY CHOOSE MARKET RESEARCH REPORTS?
1
Trusted By Leaders
2
Shop With Confidence
3
Customer Centric
4
Personalized Solutions
5
Secure Checkout

User login

Clients Who Trust Us

Orange, Google, Microsoft, Barclays, CassidianIntel, TPG, Elit Net, Cross Business Producers, AcmavolpakP&G, Cisco, Gemalto, General Insurance Corporation of India, Aviva, Cognizant, InoxWindB. Braun, Cobham, fiserv, Harris, Wipro, AonAl Meera, Nomura Research Institute, Tata Consultancy Services, Amara Raja, Hiranandani EnergyMunich Re, Lotte Chemical, National Post, First Data